Cargando…
Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology Analysis
The most prominent treatment for the serious cases of Crohn’s disease (CD) are biological tumour necrosis factor (TNF) inhibitors. Unfortunately, therapy nonresponse is still a serious issue in ~1/3 of CD patients. Accurate prediction of responsiveness prior to therapy start would therefore be of gr...
Autores principales: | Gole, Boris, Potočnik, Uroš |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628089/ https://www.ncbi.nlm.nih.gov/pubmed/31141991 http://dx.doi.org/10.3390/cells8060515 |
Ejemplares similares
-
Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis
por: Jezernik, Gregor, et al.
Publicado: (2022) -
Gene Ontology Analysis Highlights Biological Processes Influencing Responsiveness to Biological Therapy in Psoriasis
por: Krušič, Martina, et al.
Publicado: (2023) -
MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy
por: Jezernik, Gregor, et al.
Publicado: (2023) -
Head and Neck Cancer Stem Cell-Enriched Spheroid Model for Anticancer Compound Screening
por: Goričan, Larisa, et al.
Publicado: (2020) -
Omics data integration identifies ELOVL7 and MMD gene regions as novel loci for adalimumab response in patients with Crohn’s disease
por: Gorenjak, Mario, et al.
Publicado: (2021)